tiprankstipranks
TipRanksTop Financial ExpertsInsidersRa Capital Management, Llc

Ra Capital Management, Llc Insider Profile

25 Followers
Ra Capital Management, Llc, Former 10% Owner. See FN(1)(6) at Achillion Pharmaceuticals, holds 10.86M shares in ARS Pharmaceuticals (Ticker: SPRY), holds 1.39M shares in LENZ Therapeutics (Ticker: LENZ), holds 12.77M shares in 89bio (Ticker: ETNB). Most recently, Ra Capital Management, Llc Bought ― shares of ARS Pharmaceuticals on Mar 27, 2024 for an estimated value of 13.29M.
tipranks
Ra Capital Management, Llc

Ra Capital Management, Llc
Achillion Pharmaceuticals (~ACHN)
Former 10% Owner. See FN(1)(6)

Ranked #26,311 out of 97,825 Corporate Insiders

Profitable Transactions

31%
36 out of 118 Profitable Transactions

Average Return

+1.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$3B
11.44%
11.44%
6.26%
6.01%
64.85% Others
A breakdown of Ra Capital Management, Llc's holdings

Insider Roles

Vaxcyte
(PCVX)
Ten Percent Owner
Janux Therapeutics Inc
(JANX)
Director, Ten Percent Owner
TG Therapeutics
(TGTX)
Ten Percent Owner
Verastem
(VSTM)
Ten Percent Owner
+34 other positions
Roles that Ra Capital Management, Llc holds in companies

Most Profitable Insider Trade

Stock:
89bio
(ETNB)
Rating:Informative Buy
Date:Jul 06, 2022 - Jul 06, 2023
Return:+497.40%
The most profitable trade made by Ra Capital Management, Llc

Ra Capital Management, Llc's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
~ACHN
Achillion Pharmaceuticals
Jan 20, 2015
Informative Buy
7.83M
$32.56M
Aclaris Therapeutics
Sep 19, 2016
Ten Percent Owner
Informative Sell
12.71M
$2.48M
KalVista Pharmaceuticals
Oct 16, 2017
Director
Informative Buy
7.22M
$6.57M
Wave Life Sciences
Dec 13, 2023
Director, Ten Percent Owner
Informative Buy
5.00M
$108.68M
RARX
Ra Pharmaceuticals
Apr 03, 2020
Uninformative Sell
233.20M
$0.00
EIDX
Eidos Therapeutics
Jun 22, 2018
Uninformative Buy
$264.30M
Arvinas Holding Company
Oct 03, 2018
Former 10% Owner
Uninformative Buy
$128.67M
Kala Pharmaceuticals
May 26, 2022
Ten Percent Owner
Informative Sell
362.05K
$55.47M
~THOR
Thoratec Corp
Dec 13, 2018
Uninformative Buy
$617.51M
scPharmaceuticals
Mar 16, 2021
Ten Percent Owner
Informative Sell
1.06M
$13.39M
STSA
Satsuma Pharmaceuticals
Jun 12, 2023
Uninformative Sell
$0.00
89bio
Mar 06, 2024
Director, Ten Percent Owner
Informative Buy
20.72M
$142.99M
THOR
Synthorx
Jan 24, 2020
Uninformative Sell
661.27M
$0.00
Enliven Therapeutics
Feb 27, 2023
Former 10% owner
Uninformative Buy
$37.38M
Phathom Pharmaceuticals
Mar 15, 2021
Ten Percent Owner
Informative Sell
31.06M
$32.71M
Verastem
Jun 29, 2020
Ten Percent Owner
Informative Sell
2.22M
$187.09M
FMTX
Forma Therapeutics Holdings
Oct 14, 2022
Uninformative Sell
$0.00
Rhythm Pharmaceuticals
Dec 04, 2020
Former 10% Owner
Informative Sell
7.03M
$172.38M
AKUS
AKOUOS
Jul 02, 2020
Uninformative Buy
$30.32M
Nkarta
Apr 28, 2022
Director, Ten Percent Owner
Informative Buy
33.00M
$77.04M
PAND
Pandion Therapeutics
Jul 22, 2020
Uninformative Buy
$106.29M
Inozyme Pharma
Jul 28, 2020
Ten Percent Owner
Uninformative Buy
$13.58M
iTeos Therapeutics
Apr 05, 2021
Director, Ten Percent Owner
Uninformative Buy
14.40M
$50.97M
Inhibrx
Aug 24, 2020
Ten Percent Owner
Uninformative Buy
$74.66M
TG Therapeutics
Sep 11, 2020
Ten Percent Owner
Informative Sell
4.09M
$195.01M
Dyne Therapeutics
Sep 23, 2020
Ten Percent Owner
Uninformative Buy
$75.12M
PMV Pharmaceuticals
Sep 29, 2020
Ten Percent Owner
Uninformative Buy
$2.84M
Vaxcyte
Oct 01, 2020
Ten Percent Owner
Informative Sell
11.24M
$356.24M
ORTX
Orchard Therapeutics
Nov 06, 2020
Informative Buy
3.56M
$165.01M
Iterum Therapeutics
Feb 08, 2021
Ten Percent Owner
Uninformative Buy
$18.18M
Vor Biopharma
Dec 09, 2022
Director, Ten Percent Owner
Uninformative Buy
50.00M
$49.14M
Solid Biosciences
Jan 12, 2024
Director, Ten Percent Owner
Informative Buy
5.00M
$58.38M
Werewolf Therapeutics
Jan 10, 2023
Director, Ten Percent Owner
Informative Buy
4.10M
$37.12M
Janux Therapeutics Inc
Jul 21, 2023
Director, Ten Percent Owner
Informative Buy
6.17M
$355.99M
Aerovate Therapeutics
Jul 06, 2021
Director, Ten Percent Owner
Uninformative Buy
$7.98M
Acumen Pharmaceuticals
Jul 25, 2023
Director, Ten Percent Owner
Informative Buy
40.00M
$56.00M
PNT
POINT Biopharma Global
Jun 30, 2021
Informative Buy
2.09M
$13.73M
Cytek Biosciences
Mar 16, 2022
Director, Ten Percent Owner
Uninformative Buy
7.19M
$84.17M
ICVX
Icosavax
Feb 20, 2024
Uninformative Sell
$0.00
Eliem Therapeutics
Aug 16, 2021
Director, Ten Percent Owner
Uninformative Buy
$2.28M
Tyra Bioscience
Feb 08, 2024
Director, Ten Percent Owner
Uninformative Buy
41.37M
$168.23M
DICE
Dice Therapeutics
Aug 09, 2023
Uninformative Sell
$0.00
AN2 Therapeutics, Inc.
Aug 22, 2023
Ten Percent Owner
Informative Buy
16.00M
$17.32M
PepGen Inc.
Feb 13, 2024
Director, Ten Percent Owner
Informative Buy
27.21M
$140.35M
ARS Pharmaceuticals
Mar 27, 2024
Director, Ten Percent Owner
Informative Buy
13.29M
$108.61M
Fulcrum Therapeutics
Jan 24, 2023
Ten Percent Owner
Informative Buy
25.00M
$106.00M
Mineralys Therapeutics, Inc.
Feb 14, 2024
Director
Uninformative Buy
22.58M
$62.29M
Black Diamond Therapeutics
Jul 07, 2023
Director
Informative Buy
4.68M
$17.95M
LENZ Therapeutics
Mar 25, 2024
Director, Ten Percent Owner
Uninformative Buy
$23.26M
Sangamo Biosciences
Feb 18, 2015
Former 10% Owner
Informative Buy
176.95K
$3.32M
BSTC
Biospecifics Technologies
Feb 26, 2010
Informative Sell
288.30K
$55.46M
DRNA
Dicerna Pharma
Dec 20, 2017
Uninformative Buy
$193.93M
SQNM
Sequenom
$27.21M
Curis
Ten Percent Owner
$63.07M
DSCI
Derma Sciences
Jan 13, 2014
Informative Sell
3.55M
$11.86M
ARDMQ
Aradigm
$49.74K
List of latest transactions for each holding click on a transaction to see Ra Capital Management, Llc's performance on stock

Ra Capital Management, Llc insider profile FAQ

What is the percentage of profitable transactions made by Ra Capital Management, Llc?
The percentage of profitable transactions made by Ra Capital Management, Llc is 31%.
    What is the average return per transaction made by Ra Capital Management, Llc?
    The average return per transaction made by Ra Capital Management, Llc is 1.00%.
      What stocks does Ra Capital Management, Llc hold?
      Ra Capital Management, Llc holds: ~ACHN, ACRS, KALV, WVE, RARX, EIDX, ARVN, KALA, ~THOR, SCPH, STSA, ETNB, THOR, ELVN, PHAT, VSTM, FMTX, RYTM, AKUS, NKTX, PAND, INZY, ITOS, INBX, TGTX, DYN, PMVP, PCVX, ORTX, ITRM, VOR, SLDB, HOWL, JANX, AVTE, ABOS, PNT, CTKB, ICVX, ELYM, TYRA, DICE, ANTX, PEPG, SPRY, FULC, MLYS, BDTX, LENZ, SGMO, BSTC, DRNA, SQNM, CRIS, DSCI, ARDMQ stocks.
        What was Ra Capital Management, Llc’s latest transaction?
        Ra Capital Management, Llc latest transaction was an Informative Buy of $13.29M.
          What was Ra Capital Management, Llc's most profitable transaction?
          Ra Capital Management, Llc’s most profitable transaction was an Informative Buy of ETNB stock on July 6, 2022. The return on the trade was 497.40%.
            What is Ra Capital Management, Llc's role in Achillion Pharmaceuticals?
            Ra Capital Management, Llc's role in Achillion Pharmaceuticals is Former 10% Owner. See FN(1)(6).
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.